Physician profile
Lambda P Msezane
NPI 1306092184
$9,503.47
in general payments reported to CMS, 2019-2025
41 companies · $868 in 2025
The $868 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $540 · 2021: $2,331 · 2022: $2,600 · 2023: $1,366 · 2024: $1,122 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,355.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $3,114.21 | 2020-2024 | Bulkamid, Axonics |
| Astellas Pharma US INC | $828.46 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $590.10 | 2023-2025 | Orgovyx, Gemtesa |
| Srs Medical Systems, INC. | $508.41 | 2019-2024 | Ct3000 Pro Base Unit, Urocuff-Dc Disposable, Single |
| Myriad Genetic Laboratories, INC. | $417.85 | 2021-2025 | Prolaris, Myrisk |
| Pfizer INC. | $360.25 | 2019-2025 | |
| Edap Technomed INC | $341.32 | 2023-2025 | |
| Dendreon Pharmaceuticals LLC | $246.64 | 2019-2024 | Provenge |
| Myovant Sciences INC. | $242.88 | 2021-2022 | |
| Boston Scientific Corporation | $233.44 | 2019-2025 | Lithovue, Ams 700, Axonics |
| Urovant Sciences INC | $231.60 | 2021-2022 | |
| Medtronic, INC. | $224.42 | 2021-2025 | Interstim |
| Teleflex LLC | $211.65 | 2023 | Urolift |
| Janssen Biotech, INC. | $209.82 | 2019-2025 | Erleada, Akeega |
| Merck Sharp & Dohme LLC | $202.91 | 2021-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lambda Msezane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.